GlassScriptPhysician profile
Uday K Reddy
NPI 1730185711
$5,915.66
in general payments reported to CMS, 2019-2025
32 companies · $745 in 2025
The $745 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $938 · 2021: $1,134 · 2022: $892 · 2023: $622 · 2024: $433 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.47 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,443.37 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,097.39 | 2019-2025 | Nucala |
| Genzyme Corporation | $434.56 | 2019-2024 | |
| Pfizer INC. | $291.01 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.87 | 2020-2024 | Cuvitru |
| Csl Behring | $235.12 | 2020-2023 | Hizentra |
| Kaleo, INC. | $232.43 | 2021-2023 | Auvi-Q |
| Genentech USA, INC. | $229.99 | 2019-2022 | |
| Optinose US, INC. | $193.17 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $137.48 | 2019-2023 | Dupixent |
| Pharming Healthcare, INC. | $134.84 | 2021-2023 | Ruconest |
| Galderma Laboratories, L.P. | $130.41 | 2025 | Nemluvio |
| Sunovion Pharmaceuticals INC. | $110.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $97.45 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $92.26 | 2021 | |
| Insmed, INC. | $91.92 | 2019 | |
| Amgen INC. | $88.63 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $81.48 | 2020-2022 | |
| Advanced Respiratory, INC | $80.82 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $48.46 | 2021-2022 | |
| Mylan Specialty L.P. | $46.96 | 2020-2021 | |
| Shire North American Group INC | $43.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.26 | 2020 | |
| Philips North America LLC | $32.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $26.83 | 2020 | |
| Pulmonx Corporation | $26.34 | 2020 | |
| Blueprint Medicines Corporation | $21.76 | 2023 | Ayvakit |
| Mayne Pharma Commercial LLC | $19.16 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.82 | 2025 | Lifevest |
| Circassia INC. | $16.44 | 2019 | |
| Lilly USA, LLC | $15.87 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.